InventisBio (SH:688382) Shang Hai Zheng Quan Bao·2026-02-26 18:52Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where all proposed resolutions were approved without any rejections [2][4]. Group 1: Meeting Details - The meeting was convened on February 26, 2026, at a location in Shanghai [5]. - The meeting was chaired by Mr. Yaolin Wang and utilized a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [2][4]. Group 2: Attendance and Legal Verification - All nine current directors and the company secretary attended the meeting, along with other senior management [3]. - The meeting was witnessed by lawyers from JunHe Law Offices, who confirmed that the procedures followed were in accordance with relevant laws and regulations, and the resolutions made were valid [6]. Group 3: Financial Performance Overview - For the fiscal year 2025, the company expects to achieve a revenue of 37.3253 million yuan, with a net loss attributable to shareholders of approximately 316.8384 million yuan [8][13]. - The decline in revenue is attributed to variations in income from technology licensing and cooperation, which differ from year to year [13]. Group 4: Operational Insights - The company's performance in 2025 was significantly influenced by its high level of research and development (R&D) investment, with several core clinical projects reaching critical stages [11]. - The company is advancing multiple clinical trials, including a Phase III trial for D-0502 and various trials for D-2570 and D-0120, indicating a robust pipeline [11][12]. Group 5: Financial Data Summary - The company anticipates a gross profit of approximately -316.5959 million yuan and a total profit of -316.5989 million yuan for 2025, reflecting an increase in losses compared to the previous year [13]. - The expected net loss after excluding non-recurring items is projected to be around -328.8111 million yuan [13].